Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib

被引：62
|
作者：
Gambacorti-Passerini, Carlo [1 ]
Mussolin, Lara [2 ]
Brugieres, Laurence [3 ]
机构：
[1] Univ Milano Bicocca, Monza, Italy
[2] Univ Padua, Padua, Italy
[3] Gustave Roussy Canc Campus, Villejuif, France
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2016年 / 374卷 / 01期
关键词：
LARGE-CELL LYMPHOMA;
D O I：
10.1056/NEJMc1511045
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：95 / 96
页数：2
相关论文
共 50 条
  • [41] First-Line Crizotinib in ALK-Positive Lung Cancer REPLY
    Solomon, Benjamin J.
    Mok, Tony
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08): : 782 - 782
  • [42] Treatment-free remission after discontinuation of ALK tyrosine kinase inhibitors (TKIs) in patients with ALK-positive anaplastic large cell lymphoma (ALCL)
    Kim, Jinyong
    Kim, Soyeon
    Kim, Tae Min
    Youk, Jeonghwan
    Kim, Miso
    Keam, Bhumsuk
    Kim, Dong-Wan
    Heo, Dae Seog
    CANCER RESEARCH, 2023, 83 (07)
  • [43] Targeting autophagy potentiates the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma
    Mitou, Geraldine
    Frentzel, Julie
    Lamant, Laurence
    Meggetto, Fabienne
    Espinos, Estelle
    Codogno, Patrice
    Brousset, Pierre
    Giuriato, Sylvie
    CANCER RESEARCH, 2015, 75
  • [44] Successful Retreatment with Crizotinib After Crizotinib-Induced Liver Failure in ALK-Positive Advanced Lung Adenocarcinoma: A Case Report
    Zhang, Xiangming
    Ni, Kai
    Chen, Huijun
    ONCOTARGETS AND THERAPY, 2023, 16 : 87 - 90
  • [45] Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma
    Mitou, Geraldine
    Frentzel, Julie
    Desquesnes, Aurore
    Le Gonidec, Sophie
    AlSaati, Talal
    Beau, Isabelle
    Lamant, Laurence
    Meggetto, Fabienne
    Espinos, Estelle
    Codogno, Patrice
    Brousset, Pierre
    Giuriato, Sylvie
    ONCOTARGET, 2015, 6 (30) : 30149 - 30164
  • [46] Immune response to ALK in ALK-positive anaplastic large cell lymphoma
    Woessmann, W.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 : 23 - 24
  • [47] Intracranial activity of ceritinib in crizotinib-pretreated and crizotinib-naive ALK-positive NSCLC patients
    不详
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2016, 9 : S50 - S50
  • [48] Efficacy and safety of crizotinib for treatment of ALK-positive NSCLC: a meta-analysis
    Du, Xing
    Zheng, Xiaoli
    Wang, Pengcheng
    Wang, Yi
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2018, 11 (11): : 11763 - 11771
  • [49] Response Rate and Outcomes in Crizotinib Treated Advanced ALK-Positive NSCLC Patients
    Davis, Keith L.
    Kaye, James A.
    Iyer, Shrividya
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S411 - S412
  • [50] First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
    Solomon, Benjamin J.
    Mok, Tony
    Kim, Dong-Wan
    Wu, Yi-Long
    Nakagawa, Kazuhiko
    Mekhail, Tarek
    Felip, Enriqueta
    Cappuzzo, Federico
    Paolini, Jolanda
    Usari, Tiziana
    Iyer, Shrividya
    Reisman, Arlene
    Wilner, Keith D.
    Tursi, Jennifer
    Blackhall, Fiona
    Boyer, M.
    Ganju, V.
    Hughes, B.
    Pavlakis, N.
    Solomon, B.
    Varma, S.
    Berghmans, T.
    Canon, J-L
    Demedts, I.
    Janssens, A.
    Louis, R.
    Pieters, T.
    Schallier, D.
    Surmont, V.
    da Silva, C. Maciel
    Ferreira, C-G Moreira
    Hirsh, V.
    Joy, A.
    Laberge, F.
    Morzycki, W.
    Wierzbicki, R.
    Han, B.
    Liu, X.
    Qin, S.
    Shi, Y.
    Wang, Y.
    Wu, G.
    Wu, Y-L
    Zhou, C.
    Ahvonen, J.
    Barlesi, F.
    Cadranel, J.
    Dansin, E.
    Fayette, J.
    Morere, J-F
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (23): : 2167 - 2177
12345